

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
IBEX Pharmaceuticals Inc.	10/31/2001
RECEIVING PARTY DATA	
Name:	Biomarin Enzymes Inc.
Street Address:	371 Bel Marin Keys Boulevard
Internal Address:	Suite 210
City:	Novato
State/Country:	CALIFORNIA
Postal Code:	94949
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6093563
CORRESPONDENCE DATA	
Fax Number:	(404)879-2160
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(404) 879-2161
Email:	Ronna@pabstpatent.com
Correspondent Name:	Patrea L. Pabst, Esq.
Address Line 1:	400 Colony Square, Suite 1200
Address Line 2:	Pabst Patent Group LLP
Address Line 4:	Atlanta, GEORGIA 30361
ATTORNEY DOCKET NUMBER:	IT 103
NAME OF SUBMITTER:	Rivka D. Monheit

CH \$40.00 6093563

Total Attachments: 6
 source=IT 103 Ibex Pharm to Biomarin#page1.tif
 source=IT 103 Ibex Pharm to Biomarin#page2.tif

source=IT 103 Ibex Pharm to Biomarin#page3.tif
source=IT 103 Ibex Pharm to Biomarin#page4.tif
source=IT 103 Ibex Pharm to Biomarin#page5.tif
source=IT 103 Ibex Pharm to Biomarin#page6.tif

PATENT ASSIGNMENT (UNITED STATES)

WHEREAS "IBEX Technologies R and D, Inc." is the registered applicant and owner of certain of the patents and related patent applications listed on Schedule "A" hereto;

WHEREAS "IBEX Technologies R and D, Inc." is a clerical misstatement of the correct corporate name of Technologies IBEX R & D Inc.,

WHEREAS "IBEX Technologies R and D, Inc." and Technologies IBEX R & D Inc. are one and the same entity;

WHEREAS by an agreement entitled "Agreement to Purchase or License the Intellectual Property" made as of and with effect from the 26th day of May, 1993, Technologies IBEX R & D Inc. did convey all of its right, title and interest in and to the patents and related patent applications listed on Schedule "A" hereto to, effective as of the 29th day of December 1995, to Technologies IBEX Inc.;

WHEREAS Technologies IBEX Inc. is the French form of the corporate name of IBEX Technologies Inc., and Technologies IBEX Inc. and IBEX Technologies Inc. are one and the same entity;

WHEREAS IBEX Technologies Inc. did transfer and convey all of its right, title and interest in and to the patents and related patent applications set forth in Schedule "A" hereto to IBEX Pharmaceuticals Inc., by an agreement entitled "Asset Purchase Agreement" made as of and with effect from the 2nd day of July, 1999;

WHEREAS IBEX Pharmaceuticals Inc. is also the registered applicant and owner of certain other patents and related patent applications also listed on Schedule "A" and Schedule "B" hereto;

AND WHEREAS, by an agreement entitled "United States Asset Purchase Agreement" made as of and with effect from the 9th day of October, 2001, IBEX Technologies Inc., IBEX Pharmaceuticals Inc., IBEX Technologies LLC, IBEX Technologies Corp., and Technologies IBEX R&D Inc. did transfer, assign, convey, set over, and sell, as their interests may appear, to Biomarin Enzymes Inc., certain intellectual property, including the patents and related patent applications set forth on Schedule "A" and Schedule "B" hereto;

In consideration of Ten Dollars (\$10.00), and other good and valuable

consideration, the receipt of which is hereby acknowledged, **IBEX PHARMACEUTICALS INC.**, in its own right and as the successor-in-interest to registered patent owner, **IBEX Technologies R and D, Inc.**, the office address of each of which is 5485 Pare, Montreal Quebec, H4P 1P7:

Does hereby sell, assign and transfer to **BIOMARIN ENZYMES INC.**, having a place of business at **371 Bel Marin Keys Boulevard, Suite 210, Novato, California 94949, U.S.A.**, (the "Assignee") its successors, assigns and legal representatives, the entire right, title and interest for the United States, and all other countries and jurisdictions, in and to any and all inventions and improvements which are disclosed in the patents and patent applications listed in Schedule "A" and Schedule "B" hereto and all divisional, continuation, continuation-in-part, substitute, renewal, reissue, and all other applications for Letters Patent which have been or shall be filed in the United States or elsewhere on any of said Inventions and Improvements; and in and to all original and reissued patents which have been or shall be issued in the United States or elsewhere on said inventions and improvements;

Does hereby agree that said Assignee may apply for and receive Letters Patent and re-issue patents for said inventions and improvements in its own name; and that, when requested, without charge to but at the expense of said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuation, continuation-in-part, substitute, renewal, reissue, and all other patent applications on any and all said improvements; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns, and representatives, all facts known to the undersigned relating to said improvements and the history thereof; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns and legal representatives;

Does hereby authorize and request the Commissioner of Patents and Trade Marks of the United States and of all foreign countries to issue any Letters Patent granted for

any invention or improvement disclosed in any patent applications listed in Schedule "A" and Schedule "B" or on any subsequently filed divisional, continuation, continuation-in-part, substitute, renewal, reissue and all other applications for Letters Patent which have been or shall be filed in the United States or elsewhere on any of said inventions or improvements, to Assignee, its successors, assigns and legal representatives. as the assignee of the entire interest in and to said inventions or improvements; and

Does hereby covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

The parties have requested that this Agreement and all communications and documents relating hereto be expressed in the English language. Les parties ont exigé que ce contrat ainsi que tous documents s'y rattachant soient rédigés dans la langue anglaise.

October Executed at Montreal, Quebec this 31st day of October, 2001.

IBEX PHARMACEUTICALS INC.

Per: [Signature]
I have authority to bind the corporation.

NOTARIAL ACKNOWLEDGEMENT
PROVINCE OF QUEBEC

PROVINCE OF QUEBEC)
COUNTY OF MONTREAL)

On Oct. 31, _____ 2001 before me, the undersigned, a Notary or Commissioner of Oaths in and for the Province of Quebec, County of Montreal, personally appeared Paul Boehr known to me or proved to me on the basis of satisfactory evidence to be an authorized officer of IBEX that he/she executed the within instrument, and further acknowledged to me that such corporation executed the within instrument pursuant to its bylaws or a resolution of Board of Directors.

WITNESS my hand and official seal this 31 day of October, 2001.

Claire Bergeron
NOTARY or COMMISSIONER



SCHEDULE A: U.S. PATENTS AND PATENT APPLICATIONS

Patent Title	Patent No./Application No.	Registered Assignee
Chondroitin Lyase Enzymes	6,093,583	IBEX Technologies R and D, Inc.
Chondroitin Lyase Enzymes	8,054,569	IBEX Technologies R and D, Inc.
Attenuation of Fibroblast Proliferation	USSN 60/168,518	IBEX Pharmaceuticals Inc.
Attenuation of tumor growth, metastasis and angiogenesis		IBEX Pharmaceuticals Inc.
Matrix Stabilized Enzyme Crystals	USSN 60/269,318	IBEX Pharmaceuticals Inc.

SCHEDULE B: WORLDWIDE PATENTS AND PATENT APPLICATIONS

Title of Patent	Patent No./Application No.	Registered Assignee
Attenuation of Fibroblast Proliferation	PCT/US00/32399	IBEX Pharmaceuticals Inc.
Attenuation of tumor growth, metastasis and angiogenesis	IT 106	IBEX Pharmaceuticals Inc.
Matrix Stabilized Enzyme Crystals		IBEX Pharmaceuticals Inc.